Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 4, 2014, Pages 477-481

  Wadelius, M ^a   Marshall, S E ^b   Islander, G ^c   Nordang, L ^a   Karawajczyk, M ^a   Yue, Q Y ^d   Terreehorst, I ^e   Baranova, E V ^f   Hugosson, S ^g   Skoldefors K ^h   Pirmohamed, M ⁱ   Maitland Van Der Zee, A H ^f   Alfirevic, A ⁱ   Hallberg, P ^a   Palmer, C N A ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UTRECHT UNIVERSITY   (Netherlands)

^g ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^h Hudiksvall Hospital   (Sweden)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIOEDEMA; CHEMICALLY INDUCED; CLASSIFICATION; CONSENSUS DEVELOPMENT; HEAD; HUMAN; METABOLISM; NECK; PHENOTYPE; RISK FACTOR;

ANGIOEDEMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; HEAD; HUMANS; NECK; PHENOTYPE; RISK FACTORS;

EID: 84921668512     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.138     Document Type: Review

References (46)

1. Weir, M.R. & Henrich, W.L. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr. Opin. Nephrol. Hypertens. 9, 403-411 (2000).
2. Sánchez-Borges, M. & González-Aveledo, L.A. Angiotensin-converting enzyme inhibitors and angioedema. Allergy. Asthma Immunol. Res. 2, 195-198 (2010).
3. The National Board of Health and Welfare. Swedish Prescribed Drug Register. (2013).
4. Powers, B.J. et al. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J. Gen. Intern. Med. 27, 716-729 (2012).
5. Israili, Z.H. & Hall, W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. 117, 234-242 (1992).
6. Kostis, J.B. et al. Incidence and characteristics of angioedema associated with enalapril. Arch. Intern. Med. 165, 1637-1642 (2005).
7. Miller, D.R., Oliveria, S.A., Berlowitz, D.R., Fincke, B.G., Stang, P. & Lillienfeld, D.E. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51, 1624-1630 (2008).
8. Pirmohamed, M., Aithal, G.P., Behr, E., Daly, A. & Roden, D. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin. Pharmacol. Ther. 89, 784-785 (2011).
9. Borzova, E. & Grattan, C.E.H. Angioedema. In Urticaria and Angioedema (eds. Zuberbier, T., Grattan, C.E.H., & Maurer, M.) 117-127 (Springer Berlin, Germany, 2010).
10. Kaplan, A.P. & Greaves, M.W. Angioedema. J. Am. Acad. Dermatol. 53, 373-388; quiz 389 (2005).
11. Kaplan, A.P. Angioedema. World Allergy Organ. J. 1, 103-113 (2008).
12. Jaiganesh, T. et al. Acute angioedema: recognition and management in the emergency department. Eur. J. Emerg. Med. 20, 10-17 (2013).
13. Rasmussen, E.R., Mey, K. & Bygum, A. Angiotensin-converting enzyme inhibitor-induced angioedema-a dangerous new epidemic. Acta Derm. Venereol. 94, 260-264 (2014).
14. Bas, M., Adams, V., Suvorava, T., Niehues, T., Hoffmann, T.K. & Kojda, G. Nonallergic angioedema: role of bradykinin. Allergy 62, 842-856 (2007).
15. Lewis, L.M. Angioedema: etiology, pathophysiology, current and emerging therapies. J. Emerg. Med. 45, 789-796 (2013).
16. Mahmoudpour, S.H. et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics 14, 249-260 (2013).
17. Duan, Q.L. et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am. J. Hum. Genet. 77, 617-626 (2005).
18. Woodard-Grice, A.V., Lucisano, A.C., Byrd, J.B., Stone, E.R., Simmons, W.H. & Brown, N.J. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitorassociated angioedema. Pharmacogenet. Genomics 20, 532-536 (2010).
19. Cilia La Corte, A.L. et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitorinduced angioedema. Hum. Mutat. 32, 1326-1331 (2011).
20. Pare, G. et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet. Genomics 23, 470-478 (2013).
21. Inomata, N. Recent advances in drug-induced angioedema. Allergol. Int. 61, 545-557 (2012).
22. Campbell, D.J., Krum, H. & Esler, M.D. Losartan increases bradykinin levels in hypertensive humans. Circulation 111, 315-320 (2005).
23. Hoover, T., Lippmann, M., Grouzmann, E., Marceau, F. & Herscu, P. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin. Exp. Allergy 40, 50-61 (2010).
24. Banerji, A., Clark, S., Blanda, M., LoVecchio, F., Snyder, B. & Camargo, C.A. Jr. Multicenter study of patients with angiotensin-converting enzyme inhibitorinduced angioedema who present to the emergency department. Ann. Allergy Asthma Immunol. 100, 327-332 (2008).
25. Bluestein, H.M., Hoover, T.A., Banerji, A.S., Camargo, C.A. Jr, Reshef, A. & Herscu, P. Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann. Allergy Asthma Immunol. 103, 502-507 (2009).
26. Malde, B., Regalado, J. & Greenberger, P.A. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann. Allergy Asthma Immunol. 98, 57-63 (2007).
27. Toh, S. et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch. Intern. Med. 172, 1582-1589 (2012).
28. Brown, N.J., Snowden, M. & Griffin, M.R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA 278, 232-233 (1997).
29. Beltrami, L., Zanichelli, A., Zingale, L., Vacchini, R., Carugo, S. & Cicardi, M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J. Hypertens. 29, 2273-2277 (2011).
30. Fitzharris, P. & Jordan, A. Investigating recurrent angio-oedema. BMJ 343, d6607 (2011).
31. Caldeira, D., David, C. & Sampaio, C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am. J. Cardiovasc. Drugs 12, 263-277 (2012).
32. Howes, L.G. & Tran, D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf. 25, 73-76 (2002).
33. Grant, N.N., Deeb, Z.E. & Chia, S.H. Clinical experience with angiotensinconverting enzyme inhibitor-induced angioedema. Otolaryngol. Head. Neck Surg. 137, 931-935 (2007).
34. Haymore, B.R., Yoon, J., Mikita, C.P., Klote, M.M. & DeZee, K.J. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann. Allergy Asthma Immunol. 101, 495-499 (2008).
35. Andrew, N., Gabb, G. & Del Fante, M. ACEI associated angioedema -a case study and review. Aust. Fam. Physician 40, 985-988 (2011).
36. Miller, D.G., Sweis, R.T. & Toerne, T.S. Penile angioedema developing after 3 years of ACEI therapy. J. Emerg. Med. 43, 273-275 (2012).
37. Benson, B.C., Smith, C. & Laczek, J.T. Angiotensin converting enzyme inhibitorinduced gastrointestinal angioedema: a case series and literature review. J. Clin. Gastroenterol. 47, 844-849 (2013).
38. Wakefield, Y.S., Theaker, E.D. & Pemberton, M.N. Angiotensin converting enzyme inhibitors and delayed onset, recurrent angioedema of the head and neck. Br. Dent. J. 205, 553-556 (2008).
39. Morimoto, T. et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J. Eval. Clin. Pract. 10, 499-509 (2004).
40. Shino, M., Takahashi, K., Murata, T., Iida, H., Yasuoka, Y. & Furuya, N. Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis. Am. J. Otolaryngol. 32, 624-626 (2011).
41. Powell, R.J. et al.; British Society for Allergy and Clinical Immunology (BSACI). BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin. Exp. Allergy 37, 631-650 (2007).
42. Sher, J. & Davis-Lorton, M. Angioedema with normal laboratory values: the next step. Curr. Allergy Asthma Rep. 13, 563-570 (2013).
43. Colás, C., Montoiro, R., Fraj, J., Garcés, M., Cubero, J.L. & Caballero, T. Nonhistaminergic idiopathic angioedema: clinical response to icatibant. J. Investig. Allergol. Clin. Immunol. 22, 520-521 (2012).
44. Lin, R.Y. et al. Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study. J. Allergy Clin. Immunol. 106, 65-71 (2000).
45. Rutkowski, K., Dua, S. & Nasser, S. Anaphylaxis: current state of knowledge for the modern physician. Postgrad. Med. J. 88, 458-464 (2012).
46. Sánchez-Borges, M., Capriles-Hulett, A. & Caballero-Fonseca, F. The multiple faces of nonsteroidal antiinflammatory drug hypersensitivity. J. Investig. Allergol. Clin. Immunol. 14, 329-334 (2004).